{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:40:29Z","timestamp":1793911229072,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2020-C-011"],"award-info":[{"award-number":["CSH-2020-C-011"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijantimicag.2021.106403","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T09:45:44Z","timestamp":1626601544000},"page":"106403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV"],"prefix":"10.1016","volume":"58","author":[{"given":"Yu-Lin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-6783","authenticated-orcid":false,"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-2064","authenticated-orcid":false,"given":"Chia-Jui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Huang","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shie-Shian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1858-6367","authenticated-orcid":false,"given":"Sung-Hsi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-0692","authenticated-orcid":false,"given":"Tun-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-4379","authenticated-orcid":false,"given":"Yuan-Ti","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2021.106403_bib0001","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2021"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/hiv.12878","article-title":"2019 update of the European AIDS Clinical Society guidelines for treatment of people living with HIV version 10.0","volume":"21","author":"Ryom","year":"2020","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0003","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0004","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.2147\/DDDT.S140767","article-title":"Two-drug regimens for treatment of na\u00efve HIV-1 infection and as maintenance therapy","volume":"12","author":"Corado","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.24875\/AIDSRev.19000061","article-title":"Is antiretroviral two-drug regimen the new standard for HIV treatment in naive patients?","volume":"21","author":"Dupont","year":"2019","journal-title":"AIDS Rev"},{"issue":"Suppl 4","key":"10.1016\/j.ijantimicag.2021.106403_bib0006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch?","volume":"20","author":"Moreno","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0007","doi-asserted-by":"crossref","first-page":"e25418","DOI":"10.1002\/jia2.25418","article-title":"Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA\u00ae observational database","volume":"22","author":"Pierone","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0009","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/jac\/dkv427","article-title":"Antiretroviral resistance at virological failure in the NEAT 001\/ANRS 143 trial: raltegravir plus darunavir\/ritonavir or tenofovir\/emtricitabine plus darunavir\/ritonavir as first-line ART","volume":"71","author":"Lambert-Niclot","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir\u2013rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0011","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0012","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0013","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2147\/IDR.S158341","article-title":"Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study","volume":"11","author":"Cheng","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0014","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1186\/s12879-019-4389-1","article-title":"Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan","volume":"19","author":"Weng","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0015","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1093\/jac\/dkaa287","article-title":"Impact of archived M184V\/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV","volume":"75","author":"Chen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0016","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0018","doi-asserted-by":"crossref","first-page":"ofaa356","DOI":"10.1093\/ofid\/ofaa356","article-title":"Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1: a randomized, open-label, multicenter, phase 3, noninferiority trial: the DUALIS study","volume":"7","author":"Spinner","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0019","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12879-017-2755-4","article-title":"A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data","volume":"17","author":"Capetti","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/003655400750045196","article-title":"Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment","volume":"32","author":"Penzak","year":"2000","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0021","doi-asserted-by":"crossref","first-page":"106369","DOI":"10.18632\/oncotarget.22465","article-title":"Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era","volume":"8","author":"Tsai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0022","first-page":"49","article-title":"Dyslipidemia related to antiretroviral therapy","volume":"13","author":"Estrada","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0023","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","article-title":"Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"92","author":"Kuo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0025","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0026","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0027","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"Maggi","year":"2014","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0028","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0029","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2021.106403_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2019.03.016","article-title":"Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients","volume":"54","author":"Chen","year":"2019","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:42:08Z","timestamp":1760377328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857921001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0924857921001680"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106403","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106403"}}